Erratum: Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: Insights from the ARISTOTLE trial (Eur Heart J (2012) 33 (2821-2830) DOI: 10.1093/eurheartj/ehs274);Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: Insights from the ARISTOTLE trial

European Heart Journal

Volumn 33, Issue 22, 2012, Pages 2821-2830

  Hohnloser, Stefan H ^a   Hijazi, Ziad ^b   Thomas, Laine ^c   Alexander, John H ^c   Amerena, John ^d   Hanna, Michael ^e   Keltai, Matyas ^f   Lanas, Fernando ^g   Lopes, Renato D ^c   Lopez Sendon, Jose ^h   Granger, Christopher B ^c   Wallentin, Lars ^b  

^a GOETHE UNIVERSITY   (Germany)

^b UPPSALA UNIVERSITY   (Sweden)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d DEAKIN UNIVERSITY   (Australia)

^e BRISTOL MYERS SQUIBB   (United States)

^f SEMMELWEIS UNIVERSITY   (Hungary)

^g UNIVERSIDAD DE LA FRONTERA   (Chile)

^h HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Anticoagulation; Apixaban; Atrial fibrillation; Bleeding; Stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTILIPEMIC AGENT; APIXABAN; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CYSTATIN C; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; WARFARIN;

AGED; ARTICLE; BLEEDING; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EMBOLISM; FEMALE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY FUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT;

EID: 84869100588     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehz749     Document Type: Erratum

References (22)

1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. J Am Med Assoc 2007; 298:2038-2047. (Pubitemid 350074801)
2. Soliman EZ, Prineas RJ, Go AS, Xie D, Lash JP, Rahman M, Ojo A, Teal VL, Jensvold NG, Robinson NL, Dries DL, Bazzano L, Mohler ER, Wright JT, Feldman HI. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 2010;159:1102-1107.
3. Alonso A, Lopez FL, Matsushita K, Loehr LR, Agarwal SK, Chen LY, Soliman EZ, Astor BC, Coresh J. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011;123:2946-2953.
4. Seliger SL, Gillen DL, Longstreth WT Jr, Kestenbaum B, Stehman-Breen CO. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int 2003; 64:603-609. (Pubitemid 36871932)
5. Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L, Singer DE. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009;119:1363-1369.
6. Piccini JP, Hernandez AF, Zhao X, Patel MR, Lewis WR, Peterson ED, Fonarow GC. Quality of care for atrial fibrillation among patients hospitalized for heart failure. J Am Coll Cardiol 2009;54:1280-1289.
7. Marinigh R, Lane DA, Lip GYH. Severe renal impairment and stroke prevention in atrial fibrillation. Implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol 2011;57:1339-1348.
8. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. Apix-aban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992.
9. Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, Gersh BJ, Granger CB, Hanna M, Horowitz J, Hylek EM, McMurray JJ, Verheugt FW, Wallentin L. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010;159:331-339.
10. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612.
11. Laterza OF, Price CP, Scott MG. Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 2002;48:699-707. (Pubitemid 34439101)
12. Flodin M, Jonsson AS, Hansson LO, Danielsson LA, Larsson A. Evaluation of Gentian cystatin C reagent on Abbott Ci8200 and calculation of glomerular filtration rate expressed in mL/min/1.73 m(2) from the cystatin C values in mg/L. Scand J Clin Lab Invest 2007;67:560-567. (Pubitemid 47344352)
13. Johnston N, Jernberg T, Lindahl B, Lindback J, Stridsberg M, Larsson A, Venge P, Wallentin L. Biochemical indicators of cardiac and renal function in a healthy elderly population. Clin Biochem 2004;37:210-216. (Pubitemid 38221569)
14. Al Suwaidi J, Reddan DN, Williams K, Pieper KS, Harrington RA, Califf RM, Granger CB, Ohman EM, Holmes DR Jr. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 2002;106:974-980. (Pubitemid 34925333)
15. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-952. (Pubitemid 28446646)
16. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.
17. Reinecke H, Brand E, Mesters R, Schabitz WR, Fisher M, Pavenstadt H, Breithardt G. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009;20:705-711.
18. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey. Chest 2010;138:1093-1100.
19. Fox KAA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, Paolini JF, Hankey GJ, Mahaffey KW, Patel MR, Singer DE, Califf RM. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011;32:2387-2394.
20. Abrahamson M, Olafsson I, Palsdottir A, Ulvsback M, Lundwall A, Jensson O, Grubb A. Structure and expression of the human cystatin C gene. Biochem J 1990;268:287-294. (Pubitemid 20193964)
21. Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, Price CP. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995;47:312-318.
22. Shastri S, Tighiouart H, Katz R, Rifkin DE, Fried LF, Shlipak MG, Newman AB, Sarnak MJ. Chronic kidney disease in octogenarians. Clin J Am Soc Nephrol 2011; 6:1410-1417.